Rabeprazole Sodium
Product Images NDC 50436-0302

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Rabeprazole Sodium (NDC 50436-0302). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unit Dose Services, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl504360302)

This is a description of two pharmaceutical products with their respective NDC codes, manufacturers, and other details. The first product is a delayed-release medication with the active ingredient Rabeprazole Sodium in 30000 mg concentration, packaged in a bottle with 30 tablets. Its NDC code is 50436-0302-1, and it is manufactured by Kremers Urban. The second product is not clear as the text contains several errors and gibberish characters, making it not available for evaluation.*

FDA Label Image

Figure 1 (Rabeprazole Sodium Delayed Release Tablets 1)

FDA Label Image

Figure 2 (Rabeprazole Sodium Delayed Release Tablets 2)

This text seems to be from a study that compares the effects of two dosages of RAB (presumably a medication) versus a placebo on heartburn scores. The study involves 68 participants in the placebo group, 64 participants in the RAB 10mg group, and 67 participants in the RAB 20mg group. The heartburn scores are rated on a scale of 0 to 4, with 0 being no heartburn and 4 being very severe heartburn. The data seems to be collected over a period of at least 21 days.*

FDA Label Image

Figure 3 (Rabeprazole Sodium Delayed Release Tablets 3)

This text describes the sample size of three different treatment groups, placebo which had 68 participants, RAB 10mg that had 64 participants, and RAB 20mg that had 67 participants. It likely pertains to a medical or clinical study where the efficacy of these treatments were being evaluated.*

FDA Label Image

Figure 4 (Rabeprazole Sodium Delayed Release Tablets 4)

FDA Label Image

Figure 5 (Rabeprazole Sodium Delayed Release Tablets 5)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.